After halting studies on tanezumab, a drug that is extremely good at relieving pain and improving function in patients with moderate to severe osteoarthritis, a small phase II clinical trial has reported just a few slight side effects, and considerable improvement in the condition of patients. Details of the 16-week trial have been published in the New England Journal of Medicine...
More...
More...